Article Text

PDF

GW23-e1164
EFFECTS OF METFORMIN ON THE BLOOD LIPID PROFILE AND INSULIN SENSITIVITY IN OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME
  1. Erhong Zhang,
  2. Ping Wang,
  3. Xiaoyan Li,
  4. Weijie Xing,
  5. Xin Tao,
  6. Xin Tao
  1. The Third Affiliated Hospital of Sun Yat-Sen University

    Abstract

    Objectives To evaluate the effects of 3 months of metformin therapy on various blood lipid factors and insulin sensitivity in obese women with PCOS.

    Methods Seventeen obese PCOS women (body mass index (BMI) ≥24 kg/m (2)), aged 20–36 years, were included in the study from the department of infertility and sexual medicine at the Third Affiliated Hospital of Sun Yat-Sen University between February 2011 and December 2011. The hormonal and metabolic parameters, including sexual hormone levels, glucose, insulin, and fasting lipids levels, were evaluated before treatment. Metformin (1500 mg/day) was administered for 3 months. After 3 months of therapy, they were resample.

    Results BMI were significantly decreased after 3 months of metformin treatment (25.52±3.51 vs 22.45±3.72, p<0.05). Serum total cholesterol (5.03±0.98 vs 4.70±0.75, p<0.05), triglycerides (1.81±0.97 vs 1.68±0.78, p<0.05), and serum testosterone (2.86±0.52 vs 1.76±0.45, p<0.05) were all reduced. Insulin resistance measured by homeostasis model assessment (HOMA) method was significantly decreased (4.51±0.68 vs 4.01±0.49, p<0.05).

    Conclusions Metformin therapy for 3 months is effective in improving insulin sensitivity and some cardiovascular risk biomarkers in obese women with PCOS.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.